Tag: Cancer: Lymphoma
Chemo-Radiation Combo Tied to Higher Survival in Peds Hodgkin
Five-year overall survival higher in patients who receive combined tx than those treated with chemo alone
Childhood Hodgkin Lymphoma Survivors at Risk for Later Cancers
Survivors have 14-fold increased risk for developing a solid subsequent malignant neoplasm
American Society of Hematology, Dec. 1-4
The 60th American Society of Hematology Annual Meeting and Exposition The annual meeting of the American Society of Hematology was held from Dec....
ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events
ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
Immunotherapy boosts later therapy for relapsed, refractory non-Hodgkin, Hodgkin lymphoma
FDA Approves First Biosimilar to Non-Hodgkin’s Lymphoma Drug
Truxima approved to treat adults with CD20-positive, B-cell non-Hodgkin's lymphoma
FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
Adcetris approved in combination with chemo to treat systemic anaplastic large cell lymphoma
Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
Duvelisib extended progression-free survival to 13.3 months versus 9.9 months for ofatumumab
Rituximab + Lenalidomide Effective in Follicular Lymphoma
Response rate, progression-free survival comparable to those seen with rituximab-chemotherapy
FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome
